Drug Profile
CB 182804
Alternative Names: CB-182,804Latest Information Update: 17 Mar 2011
Price :
$50
*
At a glance
- Originator BioSource Pharm
- Developer Cubist Pharmaceuticals
- Class Antibacterials; Lipopeptides; Peptides
- Mechanism of Action Cell wall inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Gram-negative infections
Most Recent Events
- 18 Feb 2009 Phase-I clinical trials in Gram-negative infections in USA (IV)